Australia has its own regulatory pathway for GLP-1 medications, governed by the Therapeutic Goods Administration (TGA) and the Pharmaceutical Benefits Scheme (PBS). If you're based in Australia and considering weight loss medication, here's an overview of what's available.
What's available in Australia?
- Ozempic (semaglutide) — TGA-approved and PBS-listed for Type 2 diabetes. Widely available. Often prescribed off-label for weight loss, contributing to supply shortages
- Wegovy (semaglutide) — TGA-approved for weight management. PBS listing for obesity has been under consideration, with access primarily through private prescription
- Saxenda (liraglutide) — TGA-approved for weight management. Available on private prescription
- Mounjaro (tirzepatide) — TGA-approved for Type 2 diabetes. Approval for weight management has been progressing through the regulatory process
PBS coverage
The Pharmaceutical Benefits Scheme subsidises medication costs for eligible Australians. As of early 2026, PBS coverage for GLP-1 medications primarily applies to their use in Type 2 diabetes (Ozempic). Weight management indications have been under review, and PBS listings for obesity use would significantly reduce out-of-pocket costs for eligible patients.
Without PBS coverage, the out-of-pocket costs for weight loss medications in Australia are substantial — typically AUD $300–$500 per month for Wegovy or Saxenda on private prescription.
Eligibility
Private prescribing criteria in Australia are generally similar to the UK:
- BMI of 30 or above, or
- BMI of 27 or above with at least one weight-related comorbidity
- Previous attempts at lifestyle modification
Prescriptions must be issued by a registered medical practitioner following a clinical assessment.
Supply issues
Australia has experienced significant supply shortages of Ozempic and other semaglutide products, driven partly by off-label prescribing for weight loss and global demand. The TGA has taken steps to manage supply, including restricting new prescriptions during shortage periods.
The medications work the same way everywhere
Regardless of where you're based, the drugs themselves are identical. Tirzepatide is tirzepatide and semaglutide is semaglutide — the clinical trial data, side effects, and mechanisms of action are universal. Our guides on how these medications work, side effects, and comparisons apply regardless of your country.
For specific Australian pricing, PBS updates, and provider recommendations, we recommend checking the TGA website and the PBS website for the most current information.